Novo Nordisk's sales increased by 31% to DKK 232.26 billion, and Net profit increased by 51% to DKK 83.68 billion in 2023. Analysts polled by Visible Alpha were expecting 82.55 billion kroner in net profit, while sales were estimated at 229.36 billion kroner.
Sales within Diabetes and Obesity care increased by 38% in Danish kroner to DKK 215.1 billion (42% at constant exchange rates), mainly driven by GLP-1 diabetes sales growth of 48% in Danish kroner (52% at CER) and Obesity care growing by 147% in Danish Kroner to DKK 41.6 billion (154% at CER). Rare disease sales decreased by 16% measured in Danish kroner (15% at CER) reflecting a reduction in manufacturing output.
For 2024, the company expects 18% to 26% sales growth and 21% to 29% operating profit growth at constant exchange rates. The increase in sales and operating profit in Danish kroner is expected to be 1 percentage point and 2 percentage points lower than at constant exchange rates, respectively.